• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TWEAK(肿瘤坏死因子样凋亡弱诱导剂)在肾间质炎症期间激活 CXCL16 的表达。

TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation.

机构信息

IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid and Fundación Renal Iñigo Álvarez de Toledo, Madrid, Spain.

出版信息

Kidney Int. 2012 Jun;81(11):1098-107. doi: 10.1038/ki.2011.475. Epub 2012 Jan 25.

DOI:10.1038/ki.2011.475
PMID:22278019
Abstract

TWEAK (tumor necrosis factor-like weak inducer of apoptosis) is a TNF superfamily cytokine that activates the fibroblast growth factor-inducible 14 (Fn14) receptor. Transcriptional analysis of experimental kidney tubulointerstitial inflammation showed a correlation between an upregulation of the mRNA for the transmembrane chemokine CXCL16, a T-cell chemoattractant, and Fn14 activation. Exogenous TWEAK increased mouse kidney CXCL16 expression and T-lymphocyte infiltration in vivo, processes inhibited by the NF-κB inhibitor parthenolide. Tubular cell CXCL16 was increased in a nephrotoxic tubulointerstitial inflammation model and neutralizing anti-TWEAK antibodies decreased this CXCL16 expression and lymphocyte infiltration. In human kidney biopsies with tubulointerstitial inflammation, tubular cell CXCL16 and Fn14 expressions were associated with inflammatory infiltrates. TWEAK upregulated CXCL16 mRNA expression in cultured renal tubular cells in an NF-κB-dependent manner and increased soluble and cellular CXCL16 protein. CXCL16 modestly promoted the expression of cytokines in tubular cells expressing its receptor (CXCR6) and appeared to synergize with TWEAK to promote an inflammatory response; however, it did not modulate tubular cell proliferation or survival. Thus, TWEAK upregulates the expression of the chemokine CXCL16 in tubular epithelium and this may contribute to kidney tubulointerstitial inflammation.

摘要

TWEAK(肿瘤坏死因子样凋亡弱诱导剂)是一种 TNF 超家族细胞因子,可激活成纤维细胞生长因子诱导的 14 型受体(Fn14 受体)。实验性肾小管间质性炎症的转录分析显示,跨膜趋化因子 CXCL16(一种 T 细胞趋化因子)的 mRNA 上调与 Fn14 激活之间存在相关性。外源性 TWEAK 增加了体内小鼠肾脏的 CXCL16 表达和 T 淋巴细胞浸润,这一过程被 NF-κB 抑制剂小白菊内酯所抑制。在肾毒性肾小管间质性炎症模型中,肾小管细胞的 CXCL16 增加,中和抗 TWEAK 抗体降低了这种 CXCL16 表达和淋巴细胞浸润。在伴有肾小管间质性炎症的人类肾活检组织中,肾小管细胞的 CXCL16 和 Fn14 表达与炎症浸润有关。TWEAK 以 NF-κB 依赖的方式上调培养的肾小管细胞中的 CXCL16 mRNA 表达,并增加可溶性和细胞 CXCL16 蛋白。CXCL16 适度促进表达其受体(CXCR6)的肾小管细胞中细胞因子的表达,并且似乎与 TWEAK 协同促进炎症反应;然而,它不调节肾小管细胞的增殖或存活。因此,TWEAK 上调肾小管上皮细胞中趋化因子 CXCL16 的表达,这可能导致肾小管间质性炎症。

相似文献

1
TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation.TWEAK(肿瘤坏死因子样凋亡弱诱导剂)在肾间质炎症期间激活 CXCL16 的表达。
Kidney Int. 2012 Jun;81(11):1098-107. doi: 10.1038/ki.2011.475. Epub 2012 Jan 25.
2
HMGB1 expression and secretion are increased via TWEAK-Fn14 interaction in atherosclerotic plaques and cultured monocytes.HMGB1 的表达和分泌可通过 TWEAK-Fn14 相互作用在动脉粥样硬化斑块和培养的单核细胞中增加。
Arterioscler Thromb Vasc Biol. 2013 Mar;33(3):612-20. doi: 10.1161/ATVBAHA.112.300874. Epub 2013 Jan 3.
3
Cytokine cooperation in renal tubular cell injury: the role of TWEAK.细胞因子在肾小管细胞损伤中的协同作用:肿瘤坏死因子样弱凋亡诱导因子的作用
Kidney Int. 2006 Nov;70(10):1750-8. doi: 10.1038/sj.ki.5001866. Epub 2006 Sep 27.
4
Pathological activation of canonical nuclear-factor κB by synergy of tumor necrosis factor α and TNF-like weak inducer of apoptosis in mouse acute colitis.肿瘤坏死因子α与凋亡的肿瘤坏死因子样弱诱导剂协同作用导致小鼠急性结肠炎中经典核因子κB的病理激活。
Cytokine. 2014 Sep;69(1):14-21. doi: 10.1016/j.cyto.2014.05.001. Epub 2014 May 27.
5
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice.肿瘤坏死因子样凋亡微弱诱导剂(TWEAK)增强了高脂饮食诱导的ApoE基因敲除小鼠的血管和肾脏损伤。
Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2061-8. doi: 10.1161/ATVBAHA.109.194852. Epub 2009 Sep 24.
6
Acute kidney injury transcriptomics unveils a relationship between inflammation and ageing.急性肾损伤转录组学揭示了炎症与衰老之间的关系。
Nefrologia. 2012;32(6):715-23. doi: 10.3265/Nefrologia.pre2012.Aug.11667. Epub 2012 Oct 23.
7
The cytokine TWEAK modulates renal tubulointerstitial inflammation.细胞因子肿瘤坏死因子样弱凋亡诱导因子(TWEAK)可调节肾小管间质炎症。
J Am Soc Nephrol. 2008 Apr;19(4):695-703. doi: 10.1681/ASN.2007050577. Epub 2008 Jan 30.
8
TWEAK/Fn14 promotes pro-inflammatory cytokine secretion in hepatic stellate cells via NF-κB/STAT3 pathways.肿瘤坏死因子样弱凋亡诱导因子/成纤维细胞生长因子诱导14通过核因子κB/信号转导和转录激活因子3信号通路促进肝星状细胞分泌促炎细胞因子。
Mol Immunol. 2017 Jul;87:67-75. doi: 10.1016/j.molimm.2017.04.003. Epub 2017 Apr 12.
9
Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells.TWEAK/Fn14相互作用在肾小球系膜细胞中的促炎作用。
J Immunol. 2006 Feb 1;176(3):1889-98. doi: 10.4049/jimmunol.176.3.1889.
10
TNF-related weak inducer of apoptosis (TWEAK) regulates junctional proteins in tubular epithelial cells via canonical NF-κB pathway and ERK activation.肿瘤坏死因子相关的凋亡弱诱导因子(TWEAK)通过经典的核因子κB途径和细胞外信号调节激酶激活来调节肾小管上皮细胞中的连接蛋白。
J Cell Physiol. 2015 Jul;230(7):1580-93. doi: 10.1002/jcp.24905.

引用本文的文献

1
Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic (CKM) Syndrome.钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂对心血管-肾脏-代谢(CKM)综合征的抗氧化作用
Antioxidants (Basel). 2025 Jun 9;14(6):701. doi: 10.3390/antiox14060701.
2
An update on renal tubular injury as related to glycolipid metabolism in diabetic kidney disease.糖尿病肾病中与糖脂代谢相关的肾小管损伤研究进展
Front Pharmacol. 2025 Apr 24;16:1559026. doi: 10.3389/fphar.2025.1559026. eCollection 2025.
3
Advances in understanding and treating diabetic kidney disease: focus on tubulointerstitial inflammation mechanisms.
理解和治疗糖尿病肾病的进展:聚焦于肾小管间质性炎症机制。
Front Endocrinol (Lausanne). 2023 Oct 4;14:1232790. doi: 10.3389/fendo.2023.1232790. eCollection 2023.
4
Potential Role of Novel Cardiovascular Biomarkers in Pediatric Patients with Chronic Kidney Disease.新型心血管生物标志物在慢性肾脏病患儿中的潜在作用。
Mini Rev Med Chem. 2024;24(5):491-506. doi: 10.2174/1389557523666230523114331.
5
Activation of fibroblast growth factor-inducible 14 in the early phase of childhood IgA nephropathy.儿童 IgA 肾病早期成纤维细胞生长因子诱导蛋白 14 的激活。
PLoS One. 2021 Oct 1;16(10):e0258090. doi: 10.1371/journal.pone.0258090. eCollection 2021.
6
The TWEAK/Fn14/CD163 axis-implications for metabolic disease.TWEAK/Fn14/CD163 轴与代谢性疾病的关系。
Rev Endocr Metab Disord. 2022 Jun;23(3):449-462. doi: 10.1007/s11154-021-09688-4. Epub 2021 Sep 20.
7
Advances in Understanding the Effects of Erythropoietin on Renal Fibrosis.促红细胞生成素对肾纤维化影响的认识进展
Front Med (Lausanne). 2020 Feb 21;7:47. doi: 10.3389/fmed.2020.00047. eCollection 2020.
8
TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?TRAIL、OPG 和 TWEAK 在肾脏疾病中的作用:生物标志物还是治疗靶点?
Clin Sci (Lond). 2019 May 16;133(10):1145-1166. doi: 10.1042/CS20181116. Print 2019 May 31.
9
Serum-soluble CXCL16 in juvenile systemic lupus erythematosus: a promising predictor of disease severity and lupus nephritis.血清可溶性 CXCL16 在青少年系统性红斑狼疮中的作用:疾病严重程度和狼疮肾炎的有前景的预测指标。
Clin Rheumatol. 2018 Nov;37(11):3025-3032. doi: 10.1007/s10067-018-4203-2. Epub 2018 Jul 13.
10
Inflammation-activated CXCL16 pathway contributes to tubulointerstitial injury in mouse diabetic nephropathy.炎症激活的 CXCL16 通路导致小鼠糖尿病肾病的肾小管间质损伤。
Acta Pharmacol Sin. 2018 Jun;39(6):1022-1033. doi: 10.1038/aps.2017.177. Epub 2018 Apr 5.